Skip to content
ES
MARKETS / NASDAQ / ROIV
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Roivant Sciences Ltd. ROIV

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$8.3M
▼ 71.6% YoY
$-299.8M
$-758.6M
In brief

What this company does

We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. As of March 31, 2026, we and our subsidiaries had approximately 721 full-time employees, including 659 in the U.S. The development and commercialization of new drug products is highly competitive. We were registered as an exempted limited company in Bermuda in 2014, under the name Valor Biotechnology Ltd. In November 2014, we changed our name to Roivant Sciences Ltd.

Written from the business description in Roivant Sciences Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 20 May 2026. Every sentence was checked against that document before publication.

Growth
USD 8.3M
Revenue, FY2025 · full 6-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.0 · Net income -0.3
2.0B4.0B-0.4B-0.8B202020212022202320242025
Compound annual growth
−36.0%
−19.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −19.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4817 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6235.7% · Net -4817.3%
5000%10000%-2000%-4000%-6000%202020212022202320242025
ROE
FY2025 · ROE -6.5%
50%100%-20%-40%-60%202020212022202320242025
Gross margin—
Operating margin-6235.7%
Net margin-4817.3%
Return on assets-7.1%
EBITDAUSD -511.7M

Each USD of equity lost 7 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -758.6
-400M-800M202020212022202320242025
Net buybacks $B Dividends $B
FY2024 · Dividends — · Net buybacks 1.3
0.5B1.0B-0.2B202220232024
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 5.7B
EquityUSD 4.5B
CashUSD 1.4B
Current ratio18.37×

Equity funds 79% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.10.0
Operating income $B−0.5−1.04.5−0.9−1.4−1.1
EBITDA $B−0.5−1.04.5−0.9−1.3·
Income tax $B0.10.00.00.00.00.0
Net income $B−0.3−0.24.3−1.0−0.8−0.8
Free cash flow $B−0.8−0.8−0.8−0.9−0.7−0.6
EPS, diluted $−0.54−0.245.23−1.42−1.26−1.28
Dividend / sh $······
Payout %······
ROE %−6.5−3.2122.1−71.7−48.9−45.0
Shares out B0.720.700.810.760.690.65

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D0
Fiscal year endsMarch 31
Data on record since2020

Share this section

Download image